Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of mRNA.
June 13, 2025
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Partnership further validates Ethris’ novel technology platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of mRNA.